The Global Consortium of Entrepreneurship Centers is a group of more than 250 university entrepreneurship programs that is headquartered at Rice University’s Jones Graduate School of Business. Photo courtesy of Rice

A Houston-based academic group called out top universities and programs from around the world — including one in Houston and another in Texas — that are excelling in educating future entrepreneurs at the Global Consortium of Entrepreneurship Centers Conference last month.

The GCEC is a consortium of more than 250 university entrepreneurship programs that is headquartered at Rice University’s Jones Graduate School of Business, which has been named a top entrepreneurship program itself time and time again.

The group's annual conference was hosted at the University of Nevada, Las Vegas, in October, and more than 550 member representatives attended, according to a statement from Rice. In addition to talks, break out sessions and collaboration time, 14 universities were awarded top honors at the event.

Houston Community College's entrepreneurial initiatives won in the Excellence in Specialty Entrepreneurship Education category. The office is known for signature programs like its annual business plan competition, which has been running since 2008. It is also home to the Minority Business Development Agency, created by a grant from the Department of Commerce in 2013, and the MBDA Pandemic Recovery Center.

Additionally, the HCC Alief Hayes Campus is in partnership with the Goldman Sachs 10,000 Small Businesses program, providing 100 hours of instruction and advising and access to capital and an alumni network.

The Texas A&M University System also won in the Outstanding Contributions to Venture Creation category along with the University of St. Thomas (Minnesota). TAMU was recognized for its TEES DeepTech Ventures program. The hands-on training program operated out of Doha, Qatar last November.

Meanwhile Babson College's Arthur M. Blank Center for Entrepreneurship and Iowa State University's Pappajohn Center for Entrepreneurship were awarded the most prestigious honor at the conference. The universities received the The Nasdaq Center for Entrepreneurial Excellence Award. This was the first year that two programs received the award based on student body sizes of less than or more than 5,000 students.

Duncan Moore, a professor at the University of Rochester’s William E. Simon Graduate School of Business Administration, and Carol Reeves, associate vice provost for entrepreneurship at the University of Arkansas’ Sam M. Walton College of Business, received legacy awards for their contributions to entrepreneurship education.

Other winners included:

  • Outstanding Emerging Entrepreneurship Center (schools with less than 5,000 students)
    • Lafayette College, Dyer Center for Innovation and Entrepreneurship
  • Outstanding Emerging Entrepreneurship Center (schools with more than 5,000 students)
    • James Madison University, Gilliam Center for Entrepreneurship
    • Nova Southeastern University, Alan B. Levan-NSU Broward Center of Innovation
  • Exceptional Activities in Entrepreneurship Across Disciplines
    • Northeastern University, Center for Entrepreneurship Education
  • Excellence in Entrepreneurship Teaching and Pedagogical Innovation
    • Stanford University, Stanford Technology Ventures Program
  • Outstanding Student Engagement & Leadership (schools with less than 5,000 students)
    • London Business School, Institute of Entrepreneurship and Private Capital
  • Outstanding Student Engagement & Leadership (schools with more than 5,000 students)
    • Marquette University, 707 Hub
  • Exceptional Contributions in Entrepreneurship Research
    • Florida Atlantic University, Adams Center for Entrepreneurship
  • GCEC Center of Entrepreneurial Leadership
    • UNLV, Troesh Center for Entrepreneurship and Innovation
The 2023 GCEC Conference will be held in Dallas next October at the University of Texas at Dallas.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”